Candesartan cilexetil; hydrochlorothiazide
Candesartan cilexetil; hydrochlorothiazide: 1 brand, 6 generics; first approved Sep 05, 2000; generic available.
Generic available: 6 ANDA applications approved.
Brand (NDA) products
- ATACAND HCTRLDANI PHARMSNDA 02109320003 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 16MG;12.5MG TABLET ORAL Rx AB 32MG;12.5MG TABLET ORAL Rx AB 32MG;25MG TABLET ORAL Rx AB
Generic (ANDA) products (6)
- PRINSTON INCANDA 20745520183 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 16MG;12.5MG TABLET ORAL Rx AB 32MG;12.5MG TABLET ORAL Rx AB 32MG;25MG TABLET ORAL Rx AB - ZYDUS LIFESCIENCESANDA 20346620173 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 16MG;12.5MG TABLET ORAL Rx AB 32MG;12.5MG TABLET ORAL Rx AB 32MG;25MG TABLET ORAL Rx AB - MACLEODS PHARMSANDA 20410020153 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 16MG;12.5MG TABLET ORAL Rx AB 32MG;12.5MG TABLET ORAL Rx AB 32MG;25MG TABLET ORAL Rx AB - SENORES PHARMSANDA 20296520133 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 16MG;12.5MG TABLET ORAL Rx AB 32MG;12.5MG TABLET ORAL Rx AB 32MG;25MG TABLET ORAL Rx AB - APOTEX INCANDA 20288420123 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 16MG;12.5MG TABLET ORAL Discontinued - 32MG;12.5MG TABLET ORAL Discontinued - 32MG;25MG TABLET ORAL Discontinued - - PHARMOBEDIENTANDA 09070420123 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 16MG;12.5MG TABLET ORAL Rx AB 32MG;12.5MG TABLET ORAL Discontinued - 32MG;25MG TABLET ORAL Rx AB
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
Approvals span 2000–2018 across 7 FDA applications.
Candesartan cilexetil; hydrochlorothiazide: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Candesartan cilexetil; hydrochlorothiazide
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo
